What Happens When We Stop Dying? - Max Hodak Live

TL;DR

• 1

  Retinal implants are already restoring meaningful vision: Hodak says Science's Prima device has taken patients from being unable to recognize faces or read to reading multiple letters at a time, with one trial participant in Europe finishing a 300-page novel.

• 2

  The core thesis is that neural engineering beats drug discovery on effect size: He contrasts decade-long drug programs that often end in failure with devices like deep brain stimulators, which can improve Parkinson's symptoms in 10 seconds, or motor decoders that let ALS and paralyzed patients play video games within an hour.

• 3

  Science Corporation is not three random companies taped together: Hodak frames Prima, biohybrid BCIs, organ perfusion, and its electronics stack as one mission, building a large independent medical technology company focused on restoring lost function and eventually extending healthy life.

• 4

  BCI economics are broken unless development gets much cheaper: Hodak says new implant programs often cost $70 million to $100 million or more before reaching patients, which pushes prices up and limits access, so Science now licenses common hardware and software to help smaller BCI startups reach humans with $5 million to $10 million instead.

• 5

  Organ perfusion is, in Hodak's view, a longevity technology hiding in plain sight: He cites a Lancet case of a 17-year-old kept alive on a perfusion circuit at roughly $500,000 per month and argues that better systems could transform transplantation, pediatric heart failure, dialysis, and even artificial heart-like support worn as a backpack.

• 6

  His 2035 forecast is not subtle: Hodak says AI is real, not hitting a wall, and compares the next 20 years to the jump from horse and buggy to the moon landing, with consequences as profound and socially disorienting as earlier industrial revolutions.